- Home
- ENSC
as of 08-28-2026 3:31pm EST
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 3.9M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 22.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | 65.24 |
| 52 Week Low/High: | $0.23 - $2.75 | Next Earning Date: | 05-13-2026 |
| Revenue: | $5,066,650 | Revenue Growth: | -2.75% |
| Revenue Growth (this year): | 55.01% | Revenue Growth (next year): | 1033.97% |
| P/E Ratio: | -0.64 | Index: | N/A |
| Free Cash Flow: | -7929935.0 | FCF Growth: | N/A |
AI-Powered ENSC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ensysce Biosciences Inc. (ENSC)
Director
Avg Cost/Share
$0.50
Shares
400,000
Total Value
$198,000.00
Owned After
916,740
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| GOWER BOB G | ENSC | Director | Aug 7, 2026 | Buy | $0.50 | 400,000 | $198,000.00 | 916,740 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K BUY Aug 13, 2026 · 100% conf.
Q2 2026 Earnings
8-K BUYAug 13, 2026 · 100% conf.
1D
+9.52%
$0.38
Act: +10.59%
5D
+9.82%
$0.38
20D
+150.96%
$0.87
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K May 15, 2026
Q1 2026 Earnings
8-KMay 15, 2026
2025 Q4 Q4 2025 Earnings
8-K Mar 30, 2026
Q4 2025 Earnings
8-KMar 30, 2026
Compare ENSC vs Leading Stocks
See how ENSC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENSC Ensysce Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.